Inhibition of osteoclasts by bisphosphonate is one strategy to be explored in order to avoid a revision surgery. The purpose of this preliminary work is to synthesize hydroxyapatite–alendronate (HA–ALN) composites as carrier for ALN that could improve its site specific activity. HA–ALN composites were prepared by the co-precipitation method. Process parameters such as HA:ALN w/w ratio (1:1, 5:1 and 10:1) and HA incubation times (6, 24, 48 and 72 h) were evaluated. Morphological, physical–chemical characterization and biocompatibility tests were performed. TEM and SEM analyses confirmed ALN precipitation as fine network onto HA. The results of physical–chemical characterization confirmed the presence of ALN in the composites and its interaction with HA. ALN content resulted between 60% and 80% in the HA:ALN 5:1 and 10:1 ratios composites. ALN release reached 80% from HA–ALN 10:1 composites. Biological tests revealed that complexation with HA increased ALN biocompatibility by three times. These preliminary results demonstrated that HA–ALN composites could be considered a carrier to control ALN release.

A preliminary study on the morphological and release properties ofhydroxyapatite–alendronate composite materials

DORATI, ROSSELLA;COLONNA, CLAUDIA;BRUNI, GIOVANNA;PAVANETTO, FRANCA;GENTA, IDA;CONTI, BICE
2011-01-01

Abstract

Inhibition of osteoclasts by bisphosphonate is one strategy to be explored in order to avoid a revision surgery. The purpose of this preliminary work is to synthesize hydroxyapatite–alendronate (HA–ALN) composites as carrier for ALN that could improve its site specific activity. HA–ALN composites were prepared by the co-precipitation method. Process parameters such as HA:ALN w/w ratio (1:1, 5:1 and 10:1) and HA incubation times (6, 24, 48 and 72 h) were evaluated. Morphological, physical–chemical characterization and biocompatibility tests were performed. TEM and SEM analyses confirmed ALN precipitation as fine network onto HA. The results of physical–chemical characterization confirmed the presence of ALN in the composites and its interaction with HA. ALN content resulted between 60% and 80% in the HA:ALN 5:1 and 10:1 ratios composites. ALN release reached 80% from HA–ALN 10:1 composites. Biological tests revealed that complexation with HA increased ALN biocompatibility by three times. These preliminary results demonstrated that HA–ALN composites could be considered a carrier to control ALN release.
2011
The Clinical Immunology & Infectious Diseases category covers resources that focus on basic research in clinical and applied allergy, immunology, and infectious disease. Microbiology and virology resources are included in this category as are resources on HIV, AIDS, sexually transmitted diseases (STDs), and hospital infections.
Esperti anonimi
Inglese
Internazionale
STAMPA
28
5
395
405
The paper deals with a research work in the field of tissue engineering, a very interdisciplinary area where biotechnology, chemistry, biology, and technology play important roles with the aim of studying tissue regeneration. Inhibition of osteoclasts by bisphosphonate is one strategy to be explored in order to avoid a revision surgery. The purpose of this preliminary work is to synthesize hydroxyapatite–alendronate (HA–ALN) composites as carrier for ALN that could improve its site specific activity. HA–ALN composites were prepared by the co-precipitation method. Process parameters such as HA:ALN w/w ratio (1:1, 5:1 and 10:1) and HA incubation times (6, 24, 48 and 72 h) were evaluated. Morphological, physical–chemical characterization and biocompatibility tests were performed. TEM and SEM analyses confirmed ALN precipitation as fine network onto HA. The results of physical–chemical characterization confirmed the presence of ALN in the composites and its interaction with HA. ALN content resulted between 60% and 80% in the HA:ALN 5:1 and 10:1 ratios composites. ALN release reached 80% from HA–ALN 10:1 composites. Biological tests revealed that complexation with HA increased ALN biocompatibility by three times. These preliminary results demonstrated that HA–ALN composites could be considered a carrier to control ALN release.
Bisphosphonates; bone implant; tissue engineering; co-precipitation method; drug delivery systems
http://www.informahealthcare.com/mnc
7
info:eu-repo/semantics/article
262
Capra, Priscilla; Dorati, Rossella; Colonna, Claudia; Bruni, Giovanna; Pavanetto, Franca; Genta, Ida; Conti, Bice
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/430542
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact